See the DrugPatentWatch profile for Dantrolene
Dantrolene Dosage Information
Dosing for dantrolene varies based on the condition being treated and patient factors such as age and weight. It is typically administered intravenously for the treatment of malignant hyperthermia and orally for the management of neuroleptic malignant syndrome, spasticity, and other conditions [1].
How Much Dantrolene is Used for Malignant Hyperthermia?
For malignant hyperthermia, the recommended intravenous dose of dantrolene is 1 mg per kilogram of body weight. This dose can be repeated every five minutes until symptoms subside or a maximum of 10 mg per kilogram of body weight is reached. If a patient does not respond to treatment, it may be advisable to discontinue the drug [1].
What is the Oral Dosage for Spasticity?
When administered orally for spasticity, the initial dose of dantrolene for adults is typically 25 mg, taken once daily. This can be increased gradually to a maximum of 100 mg, four times a day, or a total daily dose of 400 mg. For children, the initial oral dose is 5 mg per kilogram of body weight per day, divided into four doses. The dose can then be increased to 25 mg per kilogram of body weight per day, or a total daily dose of 400 mg, whichever is less [1].
How is Dantrolene Administered for Neuroleptic Malignant Syndrome?
Dantrolene is administered intravenously for neuroleptic malignant syndrome, with initial doses of 1 mg per kilogram of body weight, which can be repeated every five minutes as needed. The maximum recommended dose is 10 mg per kilogram of body weight. Oral administration may follow for continued management [1].
Are There Specific Dosing Adjustments for Children or Elderly Patients?
Dosing for children generally starts at a lower initial dose compared to adults, with gradual increases based on response and tolerance. For elderly patients, while specific routine adjustments are not always mandated, their healthcare providers will consider age and potential co-existing conditions when determining the appropriate dantrolene dosage [1].
What are the Risks Associated with Dantrolene Dosing?
Potential risks include hepatotoxicity, particularly with long-term oral use, and drowsiness or dizziness. It is crucial to monitor liver function in patients receiving chronic dantrolene therapy. Patients should also be advised against driving or operating heavy machinery until they know how dantrolene affects them [1].
When Can Patent Expirations for Dantrolene Be Expected?
Information regarding specific patent expirations for dantrolene is not provided here, but such details can often be found on specialized drug patent tracking websites [2].
Who Manufactures Dantrolene?
Currently, multiple manufacturers produce dantrolene. For instance, ANI Pharmaceuticals produces a dantrolene sodium product [3].
How Does Dantrolene Work?
Dantrolene is a muscle relaxant that acts directly on skeletal muscle. It works by interfering with the release of calcium from the sarcoplasmic reticulum, which is essential for muscle contraction. This action helps to reduce muscle spasticity and, in the case of malignant hyperthermia, to correct the uncontrolled muscle activity [1].
What Are the Clinical Trial Data Regarding Dantrolene's Efficacy?
Clinical trial data supports the use of dantrolene in managing malignant hyperthermia, neuroleptic malignant syndrome, and spasticity associated with conditions like multiple sclerosis, spinal cord injury, stroke, and cerebral palsy. Studies have demonstrated its effectiveness in reducing muscle rigidity, fever, and other symptoms characteristic of these conditions [1].
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. ANI Pharmaceuticals